STAT+: More lung cancer patients see tumor responses with Mirati’s KRAS combination treatment

Mirati Therapeutics said Monday that more than 60% of patients with lung cancer showed confirmed tumor responses when its experimental KRAS-blocking drug was added to Merck’s Keytruda immunotherapy.

Click to view original post